CJC-1295

A long-acting GHRH analogue that raised growth hormone and IGF-1 in two small 2006 human studies; development stopped soon after, and no outcome trials exist.

Also known as: CJC-1295 with DAC, CJC-1295 without DAC, Modified GRF (1-29), Mod GRF 1-29, DAC:GRF
Area: Hormones
Status: Never approved anywhere; development stopped in 2006; sold for research use only

Articles on CJC-1295

HormonesHuman study

Ipamorelin: a selective growth hormone pulse, and the blend question still open

Ipamorelin releases growth hormone in a short, selective pulse. Its human record is a 1999 dosing study and a 2014 surgical trial that missed its primary endpoint; the CJC-1295 combination is where the human evidence stops.

HPR Editorial · 13 Aug 2026 · 9 min read

HormonesHuman study

CJC-1295: what two small 2006 studies showed, and why nothing followed

One version of CJC-1295 raised growth hormone for about a week in healthy adults. The other, sold as “no DAC”, has never been tested in people at all.

HPR Editorial · 4 Aug 2026 · 9 min read